News | July 05, 2023
Syngene to acquire multi-modal facility from Stelis Biopharma
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
OVAPEX is a unique formula developed by the team of scientists and doctors at Green Milk Concepts
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Subscribe To Our Newsletter & Stay Updated
